Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Golden Heights AB (publ) delays the publication of the annual report for the financial year 2021

Golden Heights Aktiebolag (publ) (”Golden Heights”) delays the publication of the annual accounts for the financial year ended 31[st] December 2021. The estimated date for publication of the annual report for 2021 is 11 May 2022. The reason for the delay of the publication is longer periods of illness of key persons in the finance department. For more information, please visit www.iduna.se or contact: Madelene Wingård, Managing Director, madelene.wingard@iduna.se, tel: +46 340 59 54 10 The information comprises such as Golden Heights Aktiebolag (publ) is obliged to publicly

REPORT ON THE FIRST QUARTER 2022

STRONG SALES GROWTH OF 55% WITH SOLID EBITA MARGIN OF 14.8% FIRST QUARTER 2022 · Net sales were SEK 7,518 m (4,858); an increase of 55%, of which 7% was organic growth. · Operating profit (EBITA) before items affecting comparability was SEK 1,114 m (801), corresponding to a margin of 14.8% (16.5%). · Items affecting comparability were SEK -159 m (-5), mainly related to an accelerated implementation of the global restructuring program. · Operating profit (EBITA) was SEK 955 m (795), corresponding to a margin of 12.7% (16.4%). · Operating profit (EBIT) was SEK 812 m (725),

Interim Report for the period January – March 2022

Decision on marketing approval for lecanemab is approaching  Events during the first quarter 2022 · Eisai commenced submission of lecanemab data in Japan for a prior assessment consultation, with the objective of obtaining faster regulatory marketing approval. Events after the first quarter · AbbVie took a strategic business decision to end its collaboration with BioArctic regarding its alpha-synuclein portfolio, including ABBV-0805. BioArctic will now, in accordance with the license agreement, take back the project and evaluate the best way forward. · A recently

Herantis Pharma Announces Successful HER-096 Initial Results with Blood-Brain Barrier Penetration in Dogs

Herantis Pharma Plc Press release 28 Apr 2022 at 9:00 am EEST   Herantis Pharma Plc (“Herantis”), an innovative biotech company developing new disease modifying therapies for Parkinson’s disease, today announced initial results of HER-096 blood-brain barrier (BBB) penetration in dogs. The results demonstrate that following a single subcutaneous administration of HER-096, the concentration of HER-096 measured from the cerebrospinal fluid (CSF) is within the pharmacologically active level. This result is aligned with previous data obtained from rats.   These data show that

Coor acquires Centrumstäd

Coor today signed an agreement relating to the acquisition of Centrumstäd, a reputable cleaning services provider in Scania in southern Sweden. Centrumstäd was founded in 1992, and the company currently has 150 employees with annual sales of some SEK 50 million. The acquisition strengthens Coor’s cleaning organization in southern Sweden and creates the right conditions for continued expansion in the region.The purchase consideration (on a cash and debt free basis) amounts to some SEK 32 million, corresponding to an EV/EBITA multiple of approximately 5.2x in relation to current EBITA. The

Enersense and Nordec have signed an agreement for Kruunuvuori Bridge project

Enersense International PlcPress release 28 April 2022 at 9:00 a.m.Enersense Works Oy and Enersense Painting Oy, subsidiaries of Enersense International Plc, a provider of zero-emission energy solutions, have signed an agreement with Nordec Oy on surface treatment work and some of the welding work for the steel structures of the Kruunuvuori Bridge project’s construction site located in Helsinki. Nordec Oy is the steel structure contractor for the Kruunuvuori Bridge. Once completed, Kruunuvuori Bridge will be the longest, tallest and most long-term bridge in Finland. It is built over

Loomis AB to publish Interim report on May 4, 2022

Loomis AB will publish the Interim report January-March 2022 on Wednesday May 4, at 3:00 p.m. (CEST).   Agenda  Wednesday May 4th, 3.00 p.m. (CEST) - Report release The report will be sent as a press release from Cision (www.cision.se) and will automatically be published on www.loomis.com when released.   Thursday May 5th, 8:30 a.m. (CEST) - Presentation slides available For presentation slides, go to www.loomis.com and choose “Financial presentation”.   Thursday May 5th, 9.00 a.m. (CEST) – Telephone conference and audio cast Analysts and media are invited to

Interim report, January–March 2022

Record revenue but with continued unsatisfying profitabilityJanuary–March 2022 · Revenue increased to TSEK 99,887 (37,131). Revenue for the period include compensation for divested production stock of TSEK 3,367 (-) · Operating profit amounted to TSEK -17,508 (-30,658) · Profit after tax amounted to TSEK -11,780 (-11,254). The result includes currency conversions and financial transaction costs of TSEK 6,393 (19,399) · Earnings per share amounted to -0,21 (-0,24) Significant events during the quarter · Announcement that Ovzon 3 satellite launch will be slightly delayed

Interim report for January – March 2022

STRONG FIRST QUARTER, MAJOR IMPROVEMENT IN MARKET OUTLOOKFinancial development Q1 2022 · Net sales increased by 177% to SEK 141.3 million (51.0). · Gross margin amounted to 47% (34). · Adjusted EBITDA amounted to SEK 6.3 million (-14.8), equivalent to an adjusted operating margin of 4.5% (-29.0). · Operating profit (EBIT) amounted to SEK 0.2 million (-22.9) including non-recurring items of SEK 0.0 million (-3.7). · Order intake increased by 31% to SEK 103.9 million (79.5). · The order backlog increased as of March 31, 2022 by 50% to SEK 744.0 million in comparison to the

Discovery confirmed in the Hamlet exploration well (PL153)

(Trondheim, 28 April 2022) Reference is made to OKEA ASA’s (OSE: OKEA) press releases of 28 February and 21 March 2022. OKEA, together with operator Neptune Energy and partners, today announces the discovery of oil and gas in the Hamlet exploration well in the Gjøa licence (PL153), where OKEA holds a 12% working interest (WI). Hydrocarbons were discovered in the target Agat Formation in both the main bore (35/9-16 S) and the side-track (35/9-16 A), drilled to confirm the discovery and acquire more data in the eastern part of the structure. In-place volumes are estimated to be in

Viaplay and Sony Pictures Television extend long-term content partnership

· New Sony Pictures series and films to stream first on Viaplay in the Nordic region · Agreement secures latest films from the Sony Pictures Universe of Marvel Characters, which includes ‘Spider-Man[™]’, ‘Venom’ and ‘Morbius’, as well as other major blockbuster franchises like ‘Jumanji’, ‘Ghostbusters’ and many more · Sony Pictures-produced series to join pipeline of international Viaplay Originals Viaplay and Sony Pictures Television (“SPT”) have agreed a multi-year extension to their long-term content partnership in the Nordic region. The latest Sony Pictures Entertainment (“SPE”)

TC TECH Sweden AB (publ) publishes its interim report

TC TECH has today published its interim report for the period January 1 to March 31, 2022.Net sales amounted to 5 795 (0) TSEK in the first quarter of 2022. In the same period, net profit/loss totalled -4 014 (-4100) TSEK. Cash flow from operating activities was -6 102 (-3 803) TSEK in the period from January 1[st] to March 31[st] 2022. Developments in the first quarter of 2022 The Board of Directors of TC TECH Sweden AB (publ) has, subject to approval at the Extraordinary General Meeting, resolved to carry out a rights issue of shares that, upon full subscription, will provide the

Sobi publishes Q1 2022 report

Swedish Orphan Biovitrum AB (publ)  (Sobi®) today announced its report for the first quarter of 2022   January – March 2022 · Total revenue SEK 4,925 M (3,661), +35 per cent, +24 per cent at constant exchange rates (CER) · Haematology revenue SEK 2,499 M (1,877), +25 per cent at CER of which Elocta® SEK 1,024 M (857), +15 per cent at CER; Alprolix® SEK 419 M (413), -3 per cent at CER; Doptelet® SEK 593 M (180), +197 per cent at CER and Aspaveli®/Empaveli™ SEK 4 M (-) · Immunology revenue SEK 2,119 M (1,554), +24 per cent at CER of which Kineret® SEK

Terveystalo Group Interim Report 1 January – 31 March, 2022: Strong growth continued in a shifting demand environment

Terveystalo Plc, Interim Report 28 April, 2022 at 09:00 EEST   This release is a summary of Terveystalo's Interim Report 1 January – 31 March, 2022. The full release is attached to this stock exchange release and is available on our website at: https://www.terveystalo.com/en/company/investors/reports-and-presentations/   January–March 2022 in brief · Revenue increased by 18.3% year-on-year to EUR 329.7 (278.7) million. The external revenue of the Sweden and others segment came to EUR 22.2 million representing 8.0 %-points of the revenue growth. · Adjusted[1)] earnings

Rottneros interim report January-March 2022

High prices gave very strong earnings· NET TURNOVER increased by 22 percent to 660 (542) MSEK, driven by higher selling prices. · THE LIST PRICE of NBSK pulp in Europe was 35 percent higher in USD and 50 percent higher in SEK compared with the first quarter of 2021. The list price has risen from 958 USD in Q1 2021 to 1 291 USD in Q1 2022. · VOLUME PRODUCED amounted to 103,2 (102,5) thousand tonnes, affected by winter problems and limited production due to high electricity prices. · SOLD VOLUME amounted to 100,0 (112,0) thousand tonnes. Demand remained strong in Europe, but sales

Stille AB: Interim Report Q1 2022

Stille AB (publ) publishes the report for the first quarter of 2022. ”A record breaking first quarter coupled with a high profitability.”, summarizes Stille CEO Hanna Ernestam Wilkman.Revenues for the first quarter increased by 72 percent to 61.6 MSEK (35.8) and the organic growth amounted to 21 percent with revenues of 43.3 MSEK. Operating profit increased to 7.5 MSEK (4.0). ”I can conclude that revenues for business unit Surgical Tables never has been higher than during the first quarter 2022. Most notable is the growth outside the US where sales increased by 52 percent compared to the

NextCell Pharma publishes Interim Report 2 2021/2022

NextCell Pharma AB (publ) (NXTCL or NextCell) publishes its Interim Report 2 for the period September 1, 2021 – February 28, 2022 The report is available on the company’s website: https://www.nextcellpharma.com/en/investors#financial-report. NextCells share is traded on Nasdaq First North Growth Market under the ticker "NXTCL". The amount in brackets refers to the corresponding period in the previous year.Second quarter (2021-12-01 until 2022-02-28)● Operating income amounted to 1 840 (1 008) TSEK.● Operating result amounted to -10 212 (-8 149) TSEK.● Earnings per share* amounted to -

Nordnet AB (publ) – interim report January-March 2022

Nordnet today publishes its interim report for the first quarter 2022. The full report is available at www.nordnetab.com- The first quarter of the year was a dramatic period in several different ways. Naturally, Russia’s invasion of Ukraine placed humanitarian, political and financial considerations high on the agenda. Despite the challenging circumstances in the world, Nordnet’s operations developed positively during the quarter, with strong underlying growth. Net savings reach as high as SEK 21 billion and our loan portfolio achieved a new record high. In conclusion, with an adjusted

Orexo Interim Report Q1 2022

Promising start to 2022 Q1 2022 highlights · Total net revenues of SEK 159.4 m (132.3) · EBITDA of SEK 2.8 m (-23.9)  · Net earnings of SEK -23.6 m (-31.5) · US Pharma segment (ZUBSOLV® US) net revenues of SEK 139.1 m (126.8), in local currency USD 14.8 m (15.1), US Pharma EBIT of SEK 84.0 m (66.1) · Cash flow from operating activities of SEK -61.6 m (-47.8), cash balance of SEK 437.8 m (725.5) · Earnings per share before and after dilution amounted to -0.69 (-0.92) · Lead product ZUBSOLV® added to NY State Medicaid MAT Preferred Drug List as of March 22 · First

Interim report Q1, January - March 2022

Summary January - March 2022 • Net sales amounted to SEK 75.6 (70.4) million, an increase of 7.4 percent. In local currencies growth was 1.2 percent. • EBIT was SEK -0.2 (6.0) million, with an EBIT margin of -0.3 (8.5) percent. • Profit/loss after tax amounted to SEK 1.4 (6.5) million. • Earnings per share before/after dilution amounted to SEK 0.07 (0.35). • Cash flow from operating activities decreased to SEK 5.5 (9.4) million.CEO’s comments We notice an increased activity in the market and during the first quarter, MSAB has signed several strategically important

MIDSONA INTERIM REPORT JANUARY–MARCH 2022

Gradual improvement over the quarter supported by price increasesJanuary–March 2022 (first quarter) ● Net sales amounted to SEK 972 million (965). ● EBITDA amounted to SEK 62 million (92) and EBITDA, before items affecting comparability, amounted to SEK 62 million (94), corresponding to a margin of 6.4 percent (9.7). ● Operating profit amounted to SEK 22 million (54) and operating profit, before items affecting comparability, amounted to SEK 22 million (56), corresponding to a margin of 2.3 percent (5.8). ● Profit for the period was SEK 12 million (33), corresponding to earnings

Immunovia Publishes Interim Report January-March 2022

January-March · Net sales amounted to kSEK 182 (123) divided between sales of tests kSEK 122 (0) and royalties kSEK 60 (123) · Net earnings amounted to MSEK -44 (-23) and ear­nings per share before and after dilution were SEK -1.95 (-1.04) · Cash flow from operating activities amounted to MSEK -46 (-30) · Cash and cash equivalents at the end of the period amounted to MSEK 240 (425) · In February the peer-reviewed, blinded study to independently validate the clinical performance of IMMray™ PanCan-d was published in Clinical and Translational Gastroenterology · The

Polygiene AB (publ.) Interim Report January 1 – March 31, 2022

A solid start to the year with growth and restored profitabilityQ1 in brief (January - March 2022) · Net sales amounted to MSEK 45.1 (42.0), a positive growth by 7.5 % · The operating profit EBITDA amounted to MSEK 9.3 (9.8), corresponding to an EBITDA margin of 20.7 (23.4) % · The gross margin amounted to 67.1 (64.8) % · The cash flow amounted to MSEK 1.4 (31.0) Events during the quarter in brief (January - March 2022) · Polygiene acquires SteriTouch · MP Activewear boosts its training collections with Polygiene · Flowfresh updates antimicrobial flooring with

SBB sells properties in Norway, Finland and Sweden for SEK 2,500m

Samhällsbyggnadsbolaget i Norden AB (publ) (“SBB”) is selling seven properties in Norway, Finland and Sweden for an agreed property value of SEK 2,500m. Of these, SEK 2,280m is used to reduce net debt. The largest property in terms of value in the portfolio is Kunnskapsveien 55 in Lilleström in Norway with OsloMet as the largest tenant and other properties consist of public offices. Of the sales proceeds, NOK 1,850m comes from sales to Public Property Invest AS (“PPI”), where SBB owns 48.8 percent. In connection with the transaction, SBB will invest NOK 215m in PPI. After the transaction,

There are no items matching the current filter
There are no more items matching the current filter
Back to top